Wacker Biotech, a contract development and manufacturing organization (CDMO) wholly owned by Wacker Chemie AG, announced a strategic collaboration with RNAV8 Bio, a Boston-based pioneer in mRNA engineering. The collaboration is aimed at progressing the development and production of mRNA-based advanced therapies for the biopharma industry..

瓦克生物技术公司（Wacker Biotech）是瓦克化学股份公司（Wacker Chemie AG）全资拥有的合同开发与制造组织（CDMO），近日宣布与总部位于波士顿的mRNA工程领域先锋企业RNAV8 Bio达成战略合作。此次合作旨在推动基于mRNA的先进疗法在生物制药行业中的开发与生产进程。

This new partnership combines Wacker Biotech’s expertise in pDNA/mRNA manufacturing and lipid nano-particle (LNP) formulation with RNAV8 Bio’s innovative mRNA engineering toolkit, which enhances the non-coding sequences of mRNA strands, known as untranslated regions (UTRs). UTRs are crucial for mRNA processing, transport, stability, and translation, and their optimization can significantly improve the efficacy of mRNA-based drug products..

这项新的合作伙伴关系结合了瓦克生物技术在pDNA/mRNA生产和脂质纳米颗粒（LNP）配方方面的专业知识，以及RNAV8生物公司创新的mRNA工程工具包，该工具包增强了mRNA链的非编码序列，即所谓的非翻译区（UTR）。UTR对于mRNA的加工、运输、稳定性和翻译至关重要，其优化可以显著提高基于mRNA的药物产品的功效。

The collaboration positions Wacker Biotech and RNAV8 Bio as premium providers in the mRNA space, offering a unique end-to-end service. The companies aim to provide a comprehensive solution that meets the growing demand for advanced mRNA therapeutics.

该合作使瓦克生物技术和RNAV8 Bio定位为mRNA领域的高端供应商，提供独特的端到端服务。这些公司旨在提供满足对先进mRNA治疗剂不断增长需求的全面解决方案。

“As the therapeutic potential of mRNA rapidly expands into high-value applications across genetic and common diseases, more predictive control over mRNA function becomes critical. RNAV8’s approach represents a major advance, enabling highly efficient and/or more durable mRNA expression at potentially lower doses.” said Devan Shah, CEO of RNAV8 Bio.

“随着mRNA的治疗潜力迅速扩展到遗传疾病和常见疾病的高价值应用中，对mRNA功能更具预测性的控制变得至关重要。RNAV8的方法代表了一项重大进步，可以在潜在更低剂量下实现高效和/或更持久的mRNA表达。”RNAV8 Bio首席执行官Devan Shah表示。

“With its impressive manufacturing capabilities and clear track record in mRNA/LNP GMP production for scale-up, Wacker Biotech is an ideal partner for RNAV8 and its therapeutics collaborators.”.

“凭借其令人印象深刻的制造能力以及在mRNA/LNP GMP生产扩大规模方面的清晰记录，Wacker Biotech是RNAV8及其治疗合作伙伴的理想选择。”

Philippe Cronet, General Manager of Wacker Biotech US Inc., added, “We are thrilled to collaborate with RNAV8 Bio. In combination with WACKER’s nucleic acids R&D team, this partnership enables us to offer clients a top-of-the-line, market-leading solution for mRNA therapeutics optimization and manufacturing.

瓦克生物技术美国公司总经理菲利普·克罗内补充道：“我们很高兴与RNAV8生物公司合作。结合瓦克的核酸研发团队，该合作伙伴关系使我们能够为客户提供一流的、市场领先的技术，用于优化和生产mRNA治疗药物。”

On clients’ behalf, we will work with RNAV8 to optimize UTR non-coding sequences to maximize the expression of mRNA in the target cells. Drug developers will have enhanced abilities to rapidly prototype, test, iterate, and scale up their mRNA therapeutics. Ultimately, this holds the promise of improving drug efficacy and accelerating the development process.”.

我们将代表客户与RNAV8合作，优化UTR非编码序列，以最大限度地提高目标细胞中mRNA的表达。药物研发人员将具备更强的能力，快速制作原型、测试、迭代并扩大其mRNA治疗药物的规模。最终，这有望提高药物疗效并加速开发进程。

https://www.bionity.com/en/news/1185958/wacker-biotech-announces-strategic-collaboration-with-rnav8-bio.html

https://www.bionity.com/en/news/1185958/wacker-biotech-announces-strategic-collaboration-with-rnav8-bio.html

Nanotechnology may improve gene therapy for blindness

纳米技术可能会改善失明的基因疗法

New research uses lipid nanoparticles to target light-sensitive cells in the eye

新研究利用脂质纳米颗粒靶向眼睛中的光敏细胞

Read news

读新闻

Most read news

最热门的新闻

1

1

Fascinating new findings: Obesity starts in the brain

引人入胜的新发现：肥胖始于大脑

2

2

A method to purify proteins with light

用光纯化蛋白质的方法

3

3

Antimalarial drug together with anticancer drug is efficient against leukemia

抗疟疾药物与抗癌药物一起对白血病有效。

4

4

Groundbreaking AI tool generates 3D map of the brain

开创性的人工智能工具生成大脑的3D地图

5

5

Extreme Mutation Hotspot in Bacteria Discovered: Study Links High Mutation Rates to Transcriptional Activation

研究发现细菌中的极端突变热点：高突变率与转录激活相关

Topics

主题

mrna therapeutics

mRNA治疗学

mRNA therapies

mRNA疗法

lipid-based nanoparticles

脂质纳米颗粒

mRNAs

mRNA

Show all

显示全部

Show less

显示更少

Organizations

组织机构

Wacker

瓦克尔